US equities |
NVDA $239.07 ▲+2.19% SPCX $167.70 ▲+5.50% MU $1,059.79 ▼-1.41% TSLA $380.41 ▲+2.65% MSFT $527.15 ▲+1.86% SNDK $1,691.08 ▼-1.68% INTC $116.59 ▼-2.29% META $742.57 ▲+1.99%
FinancialContent

Alto Neuroscience, Inc. Common Stock (NY:ANRO)

24.08 -0.72 (-2.90%)
Delayed Quote Updated: 2:54 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alto Neuroscience, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Top movers analysis in the middle of the day on 2025-10-20: top gainers and losers in today's session. ↗
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
Gapping stocks in Monday's session ↗
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Alto Neuroscience Announces $50 Million Private Placement Financing
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug ↗
FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. 
Via Stocktwits
News headline image
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
From Alto Neuroscience, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
This Electronic Arts Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
News headline image
This VSE Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
News headline image
Important Notice to Long-Term Shareholders of Alto Neuroscience, Inc. (NYSE: ANRO); Brainstorm Cell Therapeutics Inc. (OTC: BCLI); Flywire Corporation (NASDAQ: FLYW); and Ibotta, Inc. (NYSE: IBTA): Grabar Law Office is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
News headline image
Alto Neuroscience, Inc. Class Action: Levi &amp; Korsinsky Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 19, 2025 - ANRO
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Alto Neuroscience, Inc. Class Action: Levi & Korsinsky Reminds Alto Neuroscience, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 19, 2025 - ANRO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
ANRO FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Alto Neuroscience, Inc. (ANRO) of the September 19th Deadline
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Investors Who Lost Money on Alto Neuroscience, Inc. (ANRO) Should Contact Levi &amp; Korsinsky About Pending Class Action - ANRO
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Investors Who Lost Money on Alto Neuroscience, Inc. (ANRO) Should Contact Levi & Korsinsky About Pending Class Action - ANRO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
ANRO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors in Alto Neuroscience, Inc. (ANRO) of the September 19th Deadline
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Investors in Alto Neuroscience, Inc. Should Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Investors in Alto Neuroscience, Inc. Should Contact Levi &amp; Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Alto Neuroscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Alto Neuroscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
ANRO DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important September 19 Deadline in Securities Class Action - ANRO
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Alto Neuroscience, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Alto Neuroscience, Inc. Sued for Securities Law Violations - Contact Levi &amp; Korsinsky Before September 19, 2025 to Discuss Your Rights - ANRO
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
ALTO NEUROSCIENCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Alto Neuroscience, Inc. (ANRO) and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc.and Certain Officers – ANRO
From Pomerantz LLP
Via GlobeNewswire
News headline image
ANRO Deadline: Rosen Law Firm Urges Alto Neuroscience, Inc. (NYSE: ANRO) Stockholders to Contact the Firm for Information About Their Rights
From Rosen Law Firm
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >